MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $6.2M
- Sep 11 · Unusual
- Form 4 sales
- 115
- On record
- Form 144 notices
- 82
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineMay 22, 2026 2026
Sold 5,682 shares at $515.44 ($2.9M)
Levy Richard S, Director
10b5-1 planSold 20.5% of holdings ($14.3M position)22,015 shares left1.1x usual sizeFollows a Form 144Filing
- 2 Form 144 noticeNoticeJun 1, 2026 +10 days
Filed to sell 1,042 shares ($518k)
Soergel David, Officer
10b5-1 planFiling
- 3 Form 4 saleRoutineJun 1, 2026 same day
Sold 1,042 shares at $495.74 ($517k)
Soergel David, Chief Medical Officer
10b5-1 planSold 9.4% of holdings ($5.5M position)10,033 shares leftFollows a Form 144Filing
- 4 Form 4 saleNo planJul 20, 2026 +49 days
Sold 2,500 shares at $547.30 ($1.4M)
Sibold William John, President and CEO
No 10b5-1 planSold 1.2% of holdings ($116M position)209,329 shares left1x usual sizeFollows a Form 144Filing
- 5 Form 144 noticeNoticeJul 20, 2026 same day
Filed to sell 2,500 shares ($1.4M)
Sibold William John, Officer and Director
No 10b5-1 plan1x usual sizeFiling
- 6 Form 4 saleNo planAug 17, 2026 +28 days
Sold 664 shares at $514.97 ($342k)
Kelley Shannon T, General Counsel
No 10b5-1 planSold 5.5% of holdings ($6.3M position)11,474 shares left1.6x usual sizeFiling
- 7 Form 144 noticeNoticeAug 20, 2026 +3 days
Filed to sell 664 shares ($337k)
Kelley Shannon T, Officer
No 10b5-1 plan1.2x usual sizeFiling
- 8 Form 4 saleUnusualSep 11, 2026 +22 days
Sold 11,583 shares at $538.65 ($6.2M)
Sibold William John, President and CEO
10b5-1 planSold 5.5% of holdings ($113M position)197,746 shares left4.7x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (197)
Export watchlist as CSV| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Sep 11, 2026 | Sibold William John | President and CEO | Form 4 sale | 11,583 | $6.2M | 5.5% | Unusual | SEC |
| Aug 20, 2026 | Aug 20, 2026 | Kelley Shannon T | Officer | Form 144 notice | 664 | $337k | Notice | SEC | |
| Aug 17, 2026 | Aug 20, 2026 | Kelley Shannon T | General Counsel | Form 4 sale | 664 | $342k | 5.5% | No plan | SEC |
| Jul 20, 2026 | Jul 20, 2026 | Sibold William John | Officer and Director | Form 144 notice | 2,500 | $1.4M | Notice | SEC | |
| Jul 20, 2026 | Jul 20, 2026 | Sibold William John | President and CEO | Form 4 sale | 2,500 | $1.4M | 1.2% | No plan | SEC |
| Jun 1, 2026 | Jun 1, 2026 | Soergel David | Chief Medical Officer | Form 4 sale | 1,042 | $517k | 9.4% | Routine | SEC |
| Jun 1, 2026 | Jun 1, 2026 | Soergel David | Officer | Form 144 notice | 1,042 | $518k | Notice | SEC | |
| May 22, 2026 | May 22, 2026 | Levy Richard S | Director | Form 4 sale | 5,682 | $2.9M | 20.5% | Routine | SEC |
| May 22, 2026 | May 22, 2026 | Levy Richard S | Director | Form 144 notice | 5,682 | $2.9M | Notice | SEC | |
| May 18, 2026 | May 18, 2026 | Soergel David | Officer | Form 144 notice | 844 | $442k | Notice | SEC | |
| May 18, 2026 | May 18, 2026 | Soergel David | Chief Medical Officer | Form 4 sale | 844 | $435k | 7.1% | No plan | SEC |
| Mar 6, 2026 | Mar 6, 2026 | Dier Mardi | Officer | Form 144 notice | 646 | $284k | Notice | SEC | |
| Mar 6, 2026 | Mar 6, 2026 | Sibold William John | Officer and Director | Form 144 notice | 1,663 | $731k | Notice | SEC | |
| Mar 6, 2026 | Mar 6, 2026 | Kelley Shannon T | Officer | Form 144 notice | 360 | $158k | Notice | SEC | |
| Mar 6, 2026 | Mar 6, 2026 | Huntsman Carole | Officer | Form 144 notice | 419 | $184k | Notice | SEC | |
| Mar 6, 2026 | Mar 6, 2026 | Taub Rebecca | Director | Form 144 notice | 491 | $216k | Notice | SEC | |
| Mar 6, 2026 | Mar 6, 2026 | Dier Mardi | Officer | Form 144 notice | 1,336 | $587k | Notice | SEC | |
| Mar 6, 2026 | Mar 6, 2026 | Dier Mardi | EVP and CFO | Form 4 sale | 1,982 | $854k | 13.7% | Routine | SEC |
| Mar 6, 2026 | Mar 6, 2026 | Sibold William John | President and CEO | Form 4 sale | 1,663 | $718k | 1.0% | No plan | SEC |
| Mar 6, 2026 | Mar 6, 2026 | Kelley Shannon T | General Counsel | Form 4 sale | 360 | $155k | 2.9% | No plan | SEC |
| Mar 6, 2026 | Mar 6, 2026 | Huntsman Carole | Chief Commercial Officer | Form 4 sale | 419 | $181k | 3.2% | No plan | SEC |
| Mar 6, 2026 | Mar 6, 2026 | Taub Rebecca | Director | Form 4 sale | 491 | $212k | 0.1% | No plan | SEC |
| Mar 2, 2026 | Mar 2, 2026 | Dier Mardi | Officer | Form 144 notice | 1,183 | $511k | Notice | SEC | |
| Mar 2, 2026 | Mar 2, 2026 | Dier Mardi | EVP and CFO | Form 4 sale | 1,183 | $505k | 11.3% | No plan | SEC |
| Jan 26, 2026 | Jan 26, 2026 | Huntsman Carole | Officer | Form 144 notice | 340 | $163k | Notice | SEC | |
| Jan 26, 2026 | Jan 26, 2026 | Sibold William John | Officer and Director | Form 144 notice | 1,577 | $758k | Notice | SEC | |
| Jan 26, 2026 | Jan 26, 2026 | Taub Rebecca | Director | Form 144 notice | 647 | $311k | Notice | SEC | |
| Jan 26, 2026 | Jan 26, 2026 | Huntsman Carole | Officer | Form 144 notice | 570 | $274k | Notice | SEC | |
| Jan 26, 2026 | Jan 26, 2026 | Huntsman Carole | Chief Commercial Officer | Form 4 sale | 910 | $449k | 9.1% | Routine | SEC |
| Jan 26, 2026 | Jan 26, 2026 | Sibold William John | President and CEO | Form 4 sale | 1,577 | $777k | 1.1% | No plan | SEC |
| Jan 26, 2026 | Jan 26, 2026 | Taub Rebecca | Director | Form 4 sale | 647 | $319k | 0.1% | No plan | SEC |
| Jan 20, 2026 | Jan 20, 2026 | Kelley Shannon T | Officer | Form 144 notice | 263 | $132k | Notice | SEC | |
| Jan 20, 2026 | Jan 20, 2026 | Taub Rebecca | Director | Form 144 notice | 2,238 | $1.1M | Notice | SEC | |
| Jan 20, 2026 | Jan 20, 2026 | Kelley Shannon T | Officer | Form 144 notice | 429 | $215k | Notice | SEC | |
| Jan 20, 2026 | Jan 20, 2026 | Kelley Shannon T | General Counsel | Form 4 sale | 692 | $344k | 7.5% | Routine | SEC |
| Jan 20, 2026 | Jan 20, 2026 | Taub Rebecca | Director | Form 4 sale | 2,238 | $1.1M | 0.5% | No plan | SEC |
| Jan 9, 2026 | Jan 13, 2026 | Friedman Paul A | Director | Form 4 sale | 280 | $154k | 0.1% | Routine | SEC |
| Jan 9, 2026 | Jan 13, 2026 | Friedman Paul A | Director | Form 4 sale | 24,520 | $12.8M | 11.6% | Routine | SEC |
| Jan 9, 2026 | Jan 13, 2026 | Taub Rebecca | Director | Form 4 sale | 240 | $132k | 0.1% | Routine | SEC |
| Jan 9, 2026 | Jan 13, 2026 | Taub Rebecca | Director | Form 4 sale | 18,410 | $9.6M | 3.9% | Routine | SEC |
| Jan 9, 2026 | Jan 9, 2026 | Taub Rebecca | Director | Form 144 notice | 18,650 | $10.4M | Notice | SEC | |
| Dec 10, 2025 | Dec 12, 2025 | Friedman Paul A | Director | Form 4 sale | 24,800 | $13.7M | 11.7% | Routine | SEC |
| Dec 10, 2025 | Dec 12, 2025 | Taub Rebecca | Director | Form 4 sale | 18,650 | $10.3M | 3.9% | Unusual | SEC |
| Dec 10, 2025 | Dec 10, 2025 | Friedman Paul A | Director | Form 144 notice | 49,600 | $27.5M | Notice | SEC | |
| Dec 10, 2025 | Dec 10, 2025 | Taub Rebecca | Director | Form 144 notice | 18,650 | $10.3M | Notice | SEC | |
| Dec 4, 2025 | Dec 4, 2025 | Sibold William John | Officer and Director | Form 144 notice | 2,400 | $1.4M | Notice | SEC | |
| Dec 4, 2025 | Dec 4, 2025 | Sibold William John | President and CEO | Form 4 sale | 2,400 | $1.4M | 1.6% | No plan | SEC |
| Dec 2, 2025 | Dec 3, 2025 | Dier Mardi | EVP and CFO | Form 4 sale | 4,173 | $2.4M | 28.6% | Routine | SEC |
| Dec 2, 2025 | Dec 2, 2025 | Dier Mardi | Officer | Form 144 notice | 4,173 | $2.4M | Notice | SEC | |
| Nov 21, 2025 | Nov 21, 2025 | Huntsman Carole | Officer | Form 144 notice | 1,958 | $1.1M | Notice | SEC | |
| Nov 21, 2025 | Nov 21, 2025 | Huntsman Carole | Chief Commercial Officer | Form 4 sale | 1,958 | $1.1M | 16.3% | Routine | SEC |
| Nov 13, 2025 | Nov 14, 2025 | Levy Richard S | Director | Form 4 sale | 8,500 | $4.4M | 28.6% | Routine | SEC |
| Nov 13, 2025 | Nov 13, 2025 | Levy Richard S | Director | Form 144 notice | 8,500 | $4.5M | Notice | SEC | |
| Nov 5, 2025 | Nov 7, 2025 | Bate Kenneth | Director | Form 4 sale | 16,575 | $8M | 86.3% | Unusual | SEC |
| Nov 5, 2025 | Nov 5, 2025 | Bate Kenneth | Director | Form 144 notice | 16,575 | $8M | Notice | SEC | |
| Sep 9, 2025 | Sep 9, 2025 | Sibold William John | Officer and Director | Form 144 notice | 7,279 | $3.3M | Notice | SEC | |
| Sep 9, 2025 | Sep 9, 2025 | Sibold William John | President and CEO | Form 4 sale | 7,279 | $3.2M | 6.6% | No plan | SEC |
| Aug 29, 2025 | Aug 29, 2025 | Craves Fred B | Former Director | Form 144 notice | 2,900 | $1.3M | Notice | SEC | |
| Aug 21, 2025 | Aug 21, 2025 | Sibold William John | President and CEO | Form 4 sale | 7,616 | $3M | 6.5% | Routine | SEC |
| Aug 21, 2025 | Aug 21, 2025 | Sibold William John | Director, Officer | Form 144 notice | 7,616 | $3M | Notice | SEC | |
| Aug 20, 2025 | Aug 20, 2025 | Craves Fred B | Former Director | Form 144 notice | 1,000 | $390k | Notice | SEC | |
| Aug 18, 2025 | Aug 18, 2025 | Kelley Shannon T | Officer | Form 144 notice | 1,304 | $482k | Notice | SEC | |
| Aug 18, 2025 | Aug 18, 2025 | Kelley Shannon T | General Counsel | Form 4 sale | 1,304 | $480k | 12.4% | Routine | SEC |
| Aug 18, 2025 | Aug 18, 2025 | Craves Fred B | Former Director | Form 144 notice | 2,000 | $764k | Notice | SEC | |
| Aug 15, 2025 | Aug 15, 2025 | Craves Fred B | Former Director | Form 144 notice | 4,100 | $1.5M | Notice | SEC | |
| Aug 15, 2025 | Aug 15, 2025 | Bate Kenneth | Director | Form 4 sale | 10,000 | $3.7M | 79.2% | Unusual | SEC |
| Aug 15, 2025 | Aug 15, 2025 | Bate Kenneth | Director | Form 144 notice | 10,000 | $3.7M | Notice | SEC | |
| Aug 13, 2025 | Aug 13, 2025 | Friedman Paul A | Director | Form 4 sale | 129,172 | $47.8M | 40.8% | Unusual | SEC |
| Aug 13, 2025 | Aug 13, 2025 | Friedman Paul A | Director | Form 144 notice | 129,172 | $46.4M | Notice | SEC | |
| Aug 12, 2025 | Aug 13, 2025 | Taub Rebecca | Director | Form 4 sale | 46,463 | $16.5M | 9.2% | Unusual | SEC |
| Aug 12, 2025 | Aug 13, 2025 | Friedman Paul A | Director | Form 4 sale | 46,808 | $16.6M | 20.0% | Routine | SEC |
| Aug 12, 2025 | Aug 12, 2025 | Taub Rebecca | Director | Form 144 notice | 43,263 | $15.1M | Notice | SEC | |
| Aug 12, 2025 | Aug 12, 2025 | Friedman Paul A | Director | Form 144 notice | 43,605 | $15.2M | Notice | SEC | |
| Aug 11, 2025 | Aug 11, 2025 | Friedman Paul A | Director | Form 144 notice | 3,203 | $1.1M | Notice | SEC | |
| Aug 11, 2025 | Aug 11, 2025 | Taub Rebecca | Director | Form 144 notice | 3,200 | $1.1M | Notice | SEC | |
| Jul 18, 2025 | Jul 22, 2025 | Taub Rebecca | Director | Form 4 sale | 1,000 | $350k | 0.2% | Routine | SEC |
| Jul 18, 2025 | Jul 22, 2025 | Friedman Paul A | Director | Form 4 sale | 1,400 | $490k | 0.7% | Routine | SEC |
| Jul 18, 2025 | Jul 18, 2025 | Friedman Paul A | Director | Form 144 notice | 1,400 | $488k | Notice | SEC | |
| Jul 18, 2025 | Jul 18, 2025 | Taub Rebecca | Director, Officer | Form 144 notice | 1,000 | $349k | Notice | SEC | |
| Jul 17, 2025 | Jul 18, 2025 | Friedman Paul A | Director | Form 4 sale | 28,876 | $10.2M | 13.4% | Routine | SEC |
| Jul 17, 2025 | Jul 18, 2025 | Taub Rebecca | Director | Form 4 sale | 29,101 | $10.3M | 5.9% | Unusual | SEC |
| Jul 17, 2025 | Jul 17, 2025 | Taub Rebecca | Director, Officer | Form 144 notice | 2,657 | $917k | Notice | SEC | |
| Jul 17, 2025 | Jul 17, 2025 | Friedman Paul A | Director | Form 144 notice | 2,700 | $931k | Notice | SEC | |
| Jul 16, 2025 | Jul 16, 2025 | Friedman Paul A | Director | Form 144 notice | 26,176 | $8.1M | Notice | SEC | |
| Jul 16, 2025 | Jul 16, 2025 | Taub Rebecca | Director, Officer | Form 144 notice | 26,444 | $8.2M | Notice | SEC | |
| Mar 13, 2025 | Mar 14, 2025 | Craves Fred B | Director | Form 4 sale | 15,470 | $5.1M | 4.2% | Unusual | SEC |
| Mar 13, 2025 | Mar 13, 2025 | Craves Fred B | Director | Form 144 notice | 7,742 | $2.5M | Notice | SEC | |
| Mar 12, 2025 | Mar 12, 2025 | Craves Fred B | Director | Form 144 notice | 7,428 | $2.5M | Notice | SEC | |
| Mar 10, 2025 | Mar 12, 2025 | Dier Mardi | SVP and CFO | Form 4 sale | 258 | $83k | 2.4% | Routine | SEC |
| Mar 5, 2025 | Mar 7, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 14,113 | $4.8M | 79.1% | Unusual | SEC |
| Mar 5, 2025 | Mar 5, 2025 | Waltermire Robert E. | Officer | Form 144 notice | 14,113 | $4.8M | Notice | SEC | |
| Mar 3, 2025 | Mar 5, 2025 | Kelley Shannon T | General Counsel | Form 4 sale | 415 | $139k | 5.4% | Routine | SEC |
| Mar 3, 2025 | Mar 5, 2025 | Dier Mardi | SVP and CFO | Form 4 sale | 1,961 | $637k | 22.1% | Routine | SEC |
| Mar 3, 2025 | Mar 5, 2025 | Huntsman Carole | Chief Commercial Officer | Form 4 sale | 1,834 | $598k | 17.6% | Routine | SEC |
| Mar 3, 2025 | Mar 3, 2025 | Dier Mardi | Officer | Form 144 notice | 2,219 | $718k | Notice | SEC | |
| Mar 3, 2025 | Mar 3, 2025 | Kelley Shannon T | Officer | Form 144 notice | 415 | $142k | Notice | SEC | |
| Mar 3, 2025 | Mar 3, 2025 | Huntsman Carole | Officer | Form 144 notice | 1,834 | $626k | Notice | SEC | |
| Feb 28, 2025 | Mar 4, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 1,227 | $418k | 24.8% | No plan | SEC |
| Feb 28, 2025 | Feb 28, 2025 | Waltermire Robert E. | Officer | Form 144 notice | 1,227 | $418k | Notice | SEC | |
| Feb 27, 2025 | Feb 28, 2025 | Daly James M | Director | Form 4 sale | 15,470 | $5.4M | 89.0% | Unusual | SEC |
| Feb 27, 2025 | Feb 28, 2025 | Bate Kenneth | Director | Form 4 sale | 20,000 | $7.1M | 91.3% | Unusual | SEC |
| Feb 27, 2025 | Feb 27, 2025 | Daly James M | Director | Form 144 notice | 15,470 | $5.4M | Notice | SEC | |
| Feb 27, 2025 | Feb 27, 2025 | Bate Kenneth | Director | Form 144 notice | 20,000 | $7.1M | Notice | SEC | |
| Jan 24, 2025 | Jan 27, 2025 | Huntsman Carole | Chief Commercial Officer | Form 4 sale | 347 | $116k | 3.2% | No plan | SEC |
| Jan 24, 2025 | Jan 27, 2025 | Sibold William John | President and CEO | Form 4 sale | 1,584 | $531k | 2.8% | No plan | SEC |
| Jan 24, 2025 | Jan 27, 2025 | Taub Rebecca | Pres., R&D, and CMO | Form 4 sale | 648 | $217k | 0.1% | No plan | SEC |
| Jan 24, 2025 | Jan 27, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 103 | $35k | 2.0% | No plan | SEC |
| Jan 24, 2025 | Jan 24, 2025 | Taub Rebecca | Officer, Director | Form 144 notice | 648 | $220k | Notice | SEC | |
| Jan 24, 2025 | Jan 24, 2025 | Huntsman Carole | Officer | Form 144 notice | 347 | $118k | Notice | SEC | |
| Jan 24, 2025 | Jan 24, 2025 | Sibold William John | Officer, Director | Form 144 notice | 1,584 | $539k | Notice | SEC | |
| Jan 24, 2025 | Jan 24, 2025 | Waltermire Robert E. | Officer | Form 144 notice | 103 | $35k | Notice | SEC | |
| Jan 17, 2025 | Jan 17, 2025 | Taub Rebecca | Officer, Director | Form 144 notice | 1,689 | $461k | Notice | SEC | |
| Jan 17, 2025 | Jan 17, 2025 | Kelley Shannon T | Officer | Form 144 notice | 277 | $76k | Notice | SEC | |
| Jan 17, 2025 | Jan 17, 2025 | Waltermire Robert E. | Officer | Form 144 notice | 442 | $121k | Notice | SEC | |
| Jan 17, 2025 | Jan 17, 2025 | Kelley Shannon T | General Counsel | Form 4 sale | 277 | $76k | 3.5% | No plan | SEC |
| Jan 17, 2025 | Jan 17, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 442 | $121k | 8.0% | No plan | SEC |
| Jan 17, 2025 | Jan 17, 2025 | Taub Rebecca | Pres., R&D, and CMO | Form 4 sale | 1,689 | $462k | 0.4% | No plan | SEC |
| Dec 3, 2024 | Dec 5, 2024 | Craves Fred B | Director | Form 4 sale | 3,600 | $1.1M | 24.7% | No plan | SEC |
| Nov 25, 2024 | Nov 27, 2024 | Craves Fred B | Director | Form 4 sale | 3,400 | $1.2M | 18.9% | No plan | SEC |
| Nov 25, 2024 | Nov 25, 2024 | Craves Fred B | Director | Form 144 notice | 10,000 | $3.2M | Notice | SEC | |
| Nov 21, 2024 | Nov 22, 2024 | Huntsman Carole | Chief Commercial Officer | Form 4 sale | 688 | $218k | 6.0% | No plan | SEC |
| Nov 21, 2024 | Nov 21, 2024 | Huntsman Carole | Officer | Form 144 notice | 688 | $218k | Notice | SEC | |
| Nov 7, 2024 | Nov 8, 2024 | Levy Richard S | Director | Form 4 sale | 5,000 | $1.8M | 31.2% | Routine | SEC |
| Nov 7, 2024 | Nov 7, 2024 | Levy Richard S | Director | Form 144 notice | 5,000 | $1.7M | Notice | SEC | |
| Nov 1, 2024 | Nov 5, 2024 | Levy Richard S | Director | Form 4 sale | 5,000 | $1.5M | 31.2% | Routine | SEC |
| Nov 1, 2024 | Nov 1, 2024 | Levy Richard S | Director | Form 144 notice | 5,000 | $1.3M | Notice | SEC | |
| Sep 10, 2024 | Sep 10, 2024 | Sibold William John | Officer, Director | Form 144 notice | 6,363 | $1.6M | Notice | SEC | |
| Sep 9, 2024 | Sep 11, 2024 | Sibold William John | President and CEO | Form 4 sale | 6,363 | $1.6M | 10.2% | No plan | SEC |
| Jun 14, 2024 | Jun 18, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 1,900 | $532k | 25.7% | Unusual | SEC |
| Jun 14, 2024 | Jun 14, 2024 | Waltermire Robert E. | Officer | Form 144 notice | 1,900 | $532k | Notice | SEC | |
| Jun 14, 2024 | Jun 14, 2024 | Lynch Brian Joseph | Officer | Form 144 notice | 17,311 | $4.7M | Notice | SEC | |
| Jun 13, 2024 | Jun 13, 2024 | Lynch Brian Joseph | Officer | Form 144 notice | 35,560 | $10.1M | Notice | SEC | |
| Jun 12, 2024 | Jun 14, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 2,000 | $570k | 26.7% | Unusual | SEC |
| Jun 12, 2024 | Jun 12, 2024 | Waltermire Robert E. | Officer | Form 144 notice | 6,000 | $1.7M | Notice | SEC | |
| Jun 11, 2024 | Jun 11, 2024 | Lynch Brian Joseph | Officer | Form 144 notice | 9,702 | $2.8M | Notice | SEC | |
| Jun 6, 2024 | Jun 6, 2024 | Lynch Brian Joseph | Officer | Form 144 notice | 21,030 | $5M | Notice | SEC | |
| May 21, 2024 | May 23, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 1,036 | $240k | 15.9% | No plan | SEC |
| May 14, 2024 | May 16, 2024 | Craves Fred B | Director | Form 4 sale | 22,489 | $4.8M | 5.2% | Routine | SEC |
| May 14, 2024 | May 14, 2024 | Craves Fred B | Director, 10% Stockholder | Form 144 notice | 22,489 | $4.8M | Notice | SEC | |
| Apr 8, 2024 | Apr 10, 2024 | Taub Rebecca | Pres., R&D, and CMO | Form 4 sale | 2,676 | $658k | 0.6% | Routine | SEC |
| Apr 8, 2024 | Apr 10, 2024 | Friedman Paul A | Director | Form 4 sale | 26,270 | $6.5M | 12.4% | Routine | SEC |
| Apr 5, 2024 | Apr 5, 2024 | Taub Rebecca | Pres., R&D, and CMO | Form 4 sale | 73,888 | $18M | 13.9% | Routine | SEC |
| Apr 5, 2024 | Apr 5, 2024 | Friedman Paul A | Director | Form 4 sale | 73,730 | $18M | 28.4% | Routine | SEC |
| Apr 3, 2024 | Apr 3, 2024 | Taub Rebecca | Officer | Form 144 notice | 76,564 | $18.7M | Notice | SEC | |
| Apr 3, 2024 | Apr 3, 2024 | Friedman Paul A | Director, Officer | Form 144 notice | 100,000 | $24.4M | Notice | SEC | |
| Apr 2, 2024 | Apr 3, 2024 | Bate Kenneth | Director | Form 4 sale | 32,489 | $8.2M | 96.4% | Routine | SEC |
| Apr 2, 2024 | Apr 3, 2024 | Daly James M | Director | Form 4 sale | 32,489 | $8.2M | 96.4% | Routine | SEC |
| Apr 1, 2024 | Apr 3, 2024 | Levy Richard S | Director | Form 4 sale | 11,000 | $2.8M | 51.6% | Routine | SEC |
| Apr 1, 2024 | Apr 1, 2024 | Daly James M | Director | Form 144 notice | 32,489 | $8.7M | Notice | SEC | |
| Apr 1, 2024 | Apr 1, 2024 | Bate Kenneth | Director | Form 144 notice | 32,489 | $8.7M | Notice | SEC | |
| Apr 1, 2024 | Apr 1, 2024 | Levy Richard S | Director | Form 144 notice | 11,000 | $2.9M | Notice | SEC | |
| Dec 15, 2023 | Dec 18, 2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 4,000 | $942k | 41.4% | Unusual | SEC |
| Dec 13, 2023 | Dec 14, 2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 3,800 | $847k | 40.1% | Unusual | SEC |
| Dec 5, 2023 | Dec 6, 2023 | Lynch Brian Joseph | SVP and General Counsel | Form 4 sale | 2,800 | $621k | 15.7% | No plan | SEC |
| Nov 30, 2023 | Dec 1, 2023 | Lynch Brian Joseph | SVP and General Counsel | Form 4 sale | 7,000 | $1.4M | 31.8% | Unusual | SEC |
| Jul 12, 2023 | Jul 12, 2023 | Gollust Keith R | Director | Form 144 notice | 5,000 | $1.1M | Notice | SEC | |
| Jun 26, 2023 | Jun 26, 2023 | Gollust Keith R | Former Affiliate | Form 144 notice | 11,477 | $2.7M | Notice | SEC | |
| Jun 26, 2023 | Jun 26, 2023 | Gollust Keith R | Former Affiliate | Form 144 notice | 43,975 | $10.3M | Notice | SEC | |
| Mar 1, 2023 | Mar 2, 2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Form 4 sale | 10,000 | $2.7M | 63.8% | Unusual | SEC |
| Jan 17, 2023 | Jan 19, 2023 | Levy Richard S | Director | Form 4 sale | 22,489 | $6.6M | 71.2% | Unusual | SEC |
| Jan 3, 2023 | Jan 6, 2023 | Lynch Brian Joseph | SVP and General Counsel | Form 4 sale | 13,000 | $3.7M | 100.0% | Unusual | SEC |
| Dec 23, 2022 | Dec 28, 2022 | Lynch Brian Joseph | SVP and General Counsel | Form 4 sale | 7,000 | $1.9M | 100.0% | Unusual | SEC |
| Dec 23, 2022 | Dec 28, 2022 | Sukhija Remy | Chief Commercial Officer | Form 4 sale | 30,000 | $8.2M | 100.0% | Unusual | SEC |
| Aug 19, 2020 | Aug 19, 2020 | Bay City Capital Management IV LLC | 10% owner | Form 4 sale | 30,000 | $3.3M | 41.2% | Unusual | SEC |
| Aug 19, 2020 | Aug 19, 2020 | Craves Fred B | Director, 10% owner | Form 4 sale | 30,000 | $3.3M | 41.2% | Unusual | SEC |
| Dec 13, 2019 | Dec 13, 2019 | Bay City Capital Fund IV Co Invesment Fund LP | 10% owner | Form 4 sale | 1.2M | $127M | 93.2% | Unusual | SEC |
| Dec 13, 2019 | Dec 13, 2019 | Craves Fred B | Director, 10% owner | Form 4 sale | 1.2M | $127M | 93.2% | Unusual | SEC |
| Nov 21, 2018 | Feb 26, 2020 | Milligan David V | Director | Form 4 sale | 20,000 | $2.3M | 100.0% | Unusual | SEC |
| Nov 19, 2018 | Feb 26, 2020 | Milligan David V | Director | Form 4 sale | 10,000 | $1.3M | 33.3% | Unusual | SEC |
| Jun 11, 2018 | Jun 13, 2018 | Schneebaum Marc R | Chief Financial Officer | Form 4 sale | 10,099 | $2.9M | 19.5% | Plan not stated | SEC |
| Jun 11, 2018 | Jun 12, 2018 | Craves Fred B | Director, 10% owner | Form 4 sale | 274,092 | $78.8M | 4.9% | Plan not stated | SEC |
| Jun 11, 2018 | Jun 12, 2018 | Friedman Paul A | Chief Executive Officer | Form 4 sale | 73,526 | $21.1M | 10.1% | Plan not stated | SEC |
| Jun 11, 2018 | Jun 12, 2018 | Bay City Capital LLC | Director, 10% owner | Form 4 sale | 280,000 | $80.5M | 71.2% | Unusual | SEC |
| Dec 14, 2015 | Dec 15, 2015 | Gollust Keith R | Director | Form 4 sale | 600,000 | $207k | 28.0% | Unusual | SEC |
| Dec 9, 2015 | Dec 9, 2015 | Gollust Keith R | Director | Form 4 sale | 745,892 | $286k | 25.9% | Unusual | SEC |
| Dec 8, 2015 | Dec 8, 2015 | Kovner Bruce | Director, 10% owner | Form 4 sale | 1.5M | $570k | 81.7% | Unusual | SEC |
| Dec 3, 2015 | Dec 3, 2015 | Kovner Bruce | Director, 10% owner | Form 4 sale | 1.4M | $610k | 61.6% | Unusual | SEC |
| Nov 30, 2015 | Nov 30, 2015 | Kovner Bruce | Director, 10% owner | Form 4 sale | 3.1M | $1.5M | 68.6% | Unusual | SEC |
| Nov 24, 2015 | Nov 24, 2015 | Kovner Bruce | Director, 10% owner | Form 4 sale | 1.2M | $516k | 31.7% | Unusual | SEC |
| Nov 20, 2015 | Nov 20, 2015 | Kovner Bruce | Director, 10% owner | Form 4 sale | 1.5M | $738k | 33.9% | Unusual | SEC |
| Nov 17, 2015 | Nov 19, 2015 | Gollust Keith R | Director | Form 4 sale | 100,000 | $41k | 3.4% | Plan not stated | SEC |
| Nov 17, 2015 | Nov 17, 2015 | Kovner Bruce | Director, 10% owner | Form 4 sale | 1.2M | $519k | 52.6% | Unusual | SEC |
| Nov 12, 2015 | Nov 12, 2015 | Kovner Bruce | Director, 10% owner | Form 4 sale | 5.4M | $3M | 70.0% | Unusual | SEC |
| Jun 18, 2012 | Jun 20, 2012 | Rieder Wendy E | VP, IP and Legal, Gen. Counsel | Form 4 sale | 7,170 | $43k | 26.6% | Unusual | SEC |
| Jun 4, 2012 | Jun 6, 2012 | Rieder Wendy E | VP, IP and Legal, Gen. Counsel | Form 4 sale | 7,170 | $39k | 26.6% | Unusual | SEC |
| Mar 1, 2012 | Mar 5, 2012 | Vukovic Vojo | SVP, Chief Medical Officer | Form 4 sale | 2,555 | $12k | 10.3% | Plan not stated | SEC |
| Mar 1, 2012 | Mar 5, 2012 | Koya Keizo | Sr. VP, Drug Development | Form 4 sale | 6,844 | $32k | 34.5% | Unusual | SEC |
| Mar 1, 2012 | Mar 5, 2012 | Ehrlich Keith S | VP, Fin. and Admin., CFO | Form 4 sale | 4,397 | $21k | 20.0% | Plan not stated | SEC |
| Apr 25, 2011 | Apr 26, 2011 | Koya Keizo | Sr. VP, Drug Development | Form 4 sale | 20,000 | $116k | 50.2% | Unusual | SEC |
| Mar 1, 2011 | Mar 3, 2011 | Vukovic Vojo | SVP, Chief Medical Officer | Form 4 sale | 2,617 | $14k | 14.9% | Plan not stated | SEC |
| Mar 1, 2011 | Mar 3, 2011 | Rieder Wendy E | VP, IP and Legal, Gen. Counsel | Form 4 sale | 5,284 | $28k | 25.5% | Unusual | SEC |
| Mar 1, 2011 | Mar 3, 2011 | Ehrlich Keith S | VP, Fin. and Admin., CFO | Form 4 sale | 2,537 | $14k | 12.6% | Plan not stated | SEC |
| Mar 1, 2011 | Mar 3, 2011 | Koya Keizo | Sr. VP, Drug Development | Form 4 sale | 18,270 | $96k | 35.6% | Unusual | SEC |
| Aug 5, 2010 | Aug 6, 2010 | Bailey Michael P | Sr. VP, Chief Comm. Officer | Form 4 sale | 4,000 | $13k | 11.9% | Plan not stated | SEC |
| Jan 5, 2009 | Jan 6, 2009 | Chadwick Jeremy G | Sr. VP, Pgm Mgmt and Clin Ops | Form 4 sale | 4,573 | $28k | 22.4% | Plan not stated | SEC |
| Jan 5, 2009 | Jan 6, 2009 | Ehrlich Keith S | VP, Fin. and Admin., CFO | Form 4 sale | 5,600 | $35k | 27.4% | Unusual | SEC |
| Jan 5, 2009 | Jan 6, 2009 | Rieder Wendy E | VP, IP and Legal, Gen. Counsel | Form 4 sale | 5,000 | $31k | 24.5% | Plan not stated | SEC |